about the product
Velgia® eco is a drug containing the active ingredient semaglutide, which is prescribed as an adjunct to a low–calorie diet and physical activity to correct and control body weight.
Solution for subcutaneous administration.
Velgia® eco is a clear, colorless or slightly brownish solution.
Solution for subcutaneous administration.
Velgia® eco is a clear, colorless or slightly brownish solution.
Drug website
welgia-eco.ruOriginal product
This product is a fully original Promomed product
On every original product you will see our brand label
Specifications
Name
Velgia® eco
Dosage form
SOLUTION FOR SUBCUTANEOUS ADMINISTRATION
Nosological classification
Drugs for the treatment of diabetes mellitus
INN
Semaglutide
Dosages
0.25 mg/g; 0.5 mg/dose; 1 mg; 1.7 mg/dose; 2.4 mg/dose
ATC code
A10BJ06
Active substance
semaglutide
Pharmacotherapeutic group
Endocrinological preparations
use
Always use the drug in full accordance with the recommendations of your doctor.
If in doubt, consult your doctor.
Recommended dose
• The recommended starting dose is 0.25 mg once a week.
• The maximum maintenance (therapeutic) dose is 2.4 mg once a day
a week.
• The dose should be gradually increased over a period of 16 weeks until
maintenance (therapeutic) dose 2.4 mg.
• The doctor will recommend that you increase the dose every 4 weeks, as indicated in
see the table below until you reach a dose of 2.4 mg.
• Do not exceed the maintenance (therapeutic) dose of 2.4 mg.
• If during the dose increase or after reaching maintenance
after the (therapeutic) dose, you will experience symptoms of gastrointestinal distress
(prolonged nausea, vomiting, or diarrhea), tell your doctor.
Perhaps the doctor will postpone the increase in the dose of the drug or reduce it to the previous one
wait for the unwanted symptoms to go away.
Route and/or method of administration
Velgia® ivf is administered subcutaneously.
Velgia® ivf should not be administered intravenously or intramuscularly.
The drug is administered once a week, at any time of the day, regardless of food intake.
The drug should be injected subcutaneously into the abdomen, thigh or upper shoulder area.
The injection site can be changed.
If necessary, the day of weekly administration can be changed, provided that the time interval between two injections is at least 3 days (more than 72 hours). After choosing a new day of administration, the drug should be continued once a week.
Before administering Velgia® eco, carefully read the instructions for using a pre-filled syringe or autoinjector, or a pen provided with the package. Consult with your doctor before the first administration of Velgia® ivf.
Help
Package leaflet
Velgia® ivf is used in adults over 18 years of age as an adjunct to a low-calorie diet and physical activity to control body weight, including weight loss and maintenance, with an initial body mass index (BMI):
• ≥ 30 kg/m2 (obese) or
• ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one overweight-related concomitant disease, such as prediabetes or type 2 diabetes mellitus (DM2), high blood pressure (hypertension), deviation from normal blood lipids (fats) (dyslipidemia), sleep-related breathing disorders (obstructive sleep apnea syndrome), or cardiovascular diseases.
If weight loss has not occurred or you feel worse, you should consult a doctor.
Seek immediate medical attention if you have administered Velgia® ivf at a higher dose than you should have. You may experience undesirable reactions such as nausea, vomiting, or diarrhea (diarrhea), which can cause dehydration (loss of body fluids).
Like all medications, Velgia® ivf can cause undesirable reactions, but they do not occur in everyone.
Discontinue use of the drug and seek immediate medical attention if one of the following signs of a severe allergic reaction occur (anaphylactic reactions, angioedema), may occur rarely (no more than 1 in 1000 people):
• difficulty breathing or swallowing
• dizziness
• fainting (drop in blood pressure) with rapid heartbeat and increased sweating
• swelling of the face, lips, tongue or throat
• severe itching of the skin, the appearance of rashes or blisters
If you have type 2 diabetes, you should inform your doctor if you experience severe visual impairment during treatment with Velgia® ivf, this may be a sign of an exacerbation of diabetic retinopathy, which may occur frequently (no more than 1 in 10 people). Seek immediate medical attention and do not administer the next dose of Velgia® ivf if one or more of the following symptoms of pancreatic inflammation (acute pancreatitis) occur, which may occur infrequently (no more than 1 in 100 people):
• severe and prolonged abdominal pain that can radiate to the back
• pain all over the abdomen
• deterioration of the condition (marked weakness, sweating, rapid heartbeat)
• increased body temperature
For more information about all possible adverse reactions and the frequency of their occurrence, see the instructions in the leaflet.
- If you are allergic to semaglutide or any other components of the drug (listed in section 6 of the leaflet)
- If you have a history of medullary thyroid cancer, including family history
- If you have multiple endocrine neoplasia (MEN) type 2, a group of hereditary endocrine diseases that cause benign and malignant neoplasms
- If you have type 1 diabetes mellitus (DM1)
- If you have diabetic ketoacidosis (an acute complication of diabetes mellitus associated with impaired carbohydrate metabolism due to insulin deficiency)
Tell your doctor that you are taking, have recently taken, or may start taking any other medications.
Semaglutide affects the absorption of other drugs in the gastrointestinal tract (GIT). It is important to take this into account for drugs that require rapid absorption into the gastrointestinal tract.
Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko St., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
Organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro
Store at a temperature of 2 to 8 ° C (in the refrigerator), but not near the freezer. Do not freeze. Store in the original packaging (pack) to protect from light. The patient is allowed to store the drug in its original packaging (pack) to protect it from light. The patient is allowed to store the drug in its original packaging (pack) to protect it from light when used at a temperature of no more than 30 ° C for no more than 28 days.
Velgia® ivf is contraindicated in children and adolescents aged 0 to 18 years.
our partners
Where to buy
